According to the companies, an objective response rate of 54.8% was observed with Daiichi Sankyo and Merck's ifinatamab deruxtecan at a 12 mg/kg dose in pretreated patients. This dose has been ...

In 2020, Daiichi Sankyo and AZ agreed to carry out a clinical trial exploring the combination of Tagrisso with patritumab deruxtecan in patients with this form of cancer who have specific EGFR ...

BASKING RIDGE, N.J. & RAHWAY, N.J.--(BUSINESS WIRE)--Results from an interim analysis of the dose-optimization part of the ongoing IDeate-Lung01 phase 2 trial showed ifinatamab deruxtecan (I-DXd ...

Advanced breast cancer is also called secondary breast cancer. You usually have gemcitabine and paclitaxel as cycles of treatment. This means you have the drugs and then a rest to let your body ...

While all skin types present their own challenges, combination skin is arguably the most difficult to manage. Combination skin means you’ve got both oily and dry spots on different areas of your ...

A trial-in-progress poster from the NSCLC cohort of a phase 1b trial evaluating the combination of datopotamab ... ICARUS-BREAST01 phase 2 study of patritumab deruxtecan (HER3-DXd) in patients ...

The research team, led by UAB Department of Pathology Professor Upender Manne, Ph.D., conducted a series of experiments using colorectal cancer cell lines, patient-derived xenografts and mouse models ...

Daiichi Sankyo granted Merck exclusive, worldwide rights (excluding Japan) to co-develop and co-commercialize Daiichi's 3 antibody-drug conjugates (ADCs) including patritumab deruxtecan (HER3-DXd ...

Ribonucleotide reductase messenger 1 is a component of the nucleotide excision repair complex that is the predominant target of the nucleoside analogue gemcitabine. Overexpression of RRM1 has been ...

“He’s got that all-round combination of: he’s very fast, he’s big, he’s strong. He is very difficult to mark and he’s prolific,” Lineker, a prominent broadcaster with the BBC and ...

(RTTNews) - IO Biotech (IOBT) announced that the Independent Data Monitoring Committee found the data from the Pivotal Phase 3 Trial of IO102-IO103 in combination with KEYTRUDA (pembrolizumab ...

Shares of US protein-based vaccine developer Novavax (Nasdaq: NVAX) closed up 8.6% and added a further 1.8% to $12.60 in after-hours trading on Friday, on a positive development for its COVID-19 ...